No Picture
News

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2021 Financial Results on November 4, 2021

SAN FRANCISCO, Oct. 21, 2021 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2021 on Thursday, November 4, 2021. […]

No Picture
News

Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2021

SAN FRANCISCO, Oct. 15, 2021 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting data from its hepatitis B clinical program and one health outcomes research abstract have been accepted for oral an… […]

No Picture
News

Vir Biotechnology to Participate in the H. C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference

SAN FRANCISCO, Oct. 06, 2021 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., chief medical officer, is scheduled to present at the H. C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference on … […]

No Picture
News

Vir Biotechnology to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

SAN FRANCISCO, Sept. 08, 2021 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare… […]

No Picture
News

Vir Biotechnology to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

SAN FRANCISCO, Sept. 07, 2021 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Howard Horn, chief financial officer, is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference on Monday, Sept… […]

No Picture
News

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2021 Financial Results on August 5, 2021

SAN FRANCISCO, July 22, 2021 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2021 on Thursday, August 5, 2021. […]

No Picture
News

Vir Biotechnology Initiates Phase 2 Clinical Trial Evaluating the Combination of VIR-2218 and VIR-3434 as a Functional Cure Regimen for Chronic Hepatitis B Virus Infection

SAN FRANCISCO, July 15, 2021 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in the Phase 2 MARCH (Monoclonal Antibody siRNA Combination against Hepatitis B) trial evaluating VIR-2218 toge… […]

No Picture
News

Vir Biotechnology to Participate in the Goldman Sachs 42nd Annual Global Healthcare Conference

SAN FRANCISCO, June 02, 2021 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare C… […]